Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of “Buy” from Brokerages

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $49.40.

A number of research analysts recently issued reports on SLP shares. KeyCorp boosted their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Stephens started coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Finally, BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 19.40% of the company’s stock.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently made changes to their positions in SLP. Conestoga Capital Advisors LLC grew its position in Simulations Plus by 15.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after buying an additional 290,414 shares during the last quarter. Tributary Capital Management LLC boosted its stake in shares of Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock worth $10,425,000 after acquiring an additional 115,122 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Simulations Plus by 28.8% in the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock worth $7,602,000 after acquiring an additional 53,092 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Simulations Plus by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock worth $20,128,000 after purchasing an additional 37,992 shares during the period. Finally, Congress Asset Management Co. lifted its holdings in shares of Simulations Plus by 22.5% during the third quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock valued at $6,613,000 after purchasing an additional 37,914 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.

Simulations Plus Stock Up 1.9 %

SLP opened at $36.19 on Friday. The company’s 50-day moving average price is $30.56 and its 200 day moving average price is $32.42. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The firm has a market cap of $727.13 million, a price-to-earnings ratio of 90.48 and a beta of 0.83.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.